AAAAAA
Results:
1-17
|
Results: 17
Authors:
WASSERMAN E
MYARA A
LOKIEC F
RIOFRIO M
IMADALOU K
BLEUZEN P
SANTONI J
TRIVIN F
HERAIT P
MAHJOUBI M
ARMAND JP
MISSET JL
CVITKOVIC E
Citation: E. Wasserman et al., BILIRUBIN (BIL) AND SN-38 - PHARMACOKINETIC PHARMACODYNAMICS CORRELATION/, Annals of oncology, 9, 1998, pp. 220-220
Authors:
SALIBA F
HAGIPANTELLI R
MISSET JL
BASTIAN G
VASSAL G
BONNAY M
HERAIT P
COTE C
MAHJOUBI M
MIGNARD D
CVITKOVIC E
Citation: F. Saliba et al., PATHOPHYSIOLOGY AND THERAPY OF IRINOTECAN-INDUCED DELAYED-ONSET DIARRHEA IN PATIENTS WITH ADVANCED COLORECTAL-CANCER - A PROSPECTIVE ASSESSMENT, Journal of clinical oncology, 16(8), 1998, pp. 2745-2751
Authors:
ROUGIER P
VANCUTSEM E
BAJETTA E
NIEDERLE N
POSSINGER K
LABIANCA R
NAVARRO M
MORANT R
BLEIBERG H
WILS J
AWAD L
HERAIT P
JACQUES C
Citation: P. Rougier et al., RANDOMIZED TRIAL OF IRINOTECAN VERSUS FLUOROURACIL BY CONTINUOUS-INFUSION AFTER FLUOROURACIL FAILURE IN PATIENTS WITH METASTATIC COLORECTAL-CANCER, Lancet, 352(9138), 1998, pp. 1407-1412
Authors:
CUNNINGHAM D
PYRHONEN S
JAMES RD
PUNT CJA
HICKISH TF
HEIKKILA R
JOHANNESEN TB
STARKHAMMAR H
TOPHAM CA
AWAD L
JACQUES C
HERAIT P
Citation: D. Cunningham et al., RANDOMIZED TRIAL OF IRINOTECAN PLUS SUPPORTIVE CARE VERSUS SUPPORTIVECARE ALONE AFTER FLUOROURACIL FAILURE FOR PATIENTS WITH METASTATIC COLORECTAL-CANCER, Lancet, 352(9138), 1998, pp. 1413-1418
Authors:
BLIJHAM G
SCHMITT C
AUSSAGE P
HENRYLAUNOIS B
JOLAIN B
HERAIT P
Citation: G. Blijham et al., COST-EFFECTIVENESS OF IRINOTECAN (CPT-11) AND BEST ESTIMATED CHEMOTHERAPY REGIMEN IN PATIENTS WITH METASTATIC COLORECTAL-CANCER AFTER FAILURE OF 5FLUOROURACIL (5FU) CONTAINING REGIMEN - RESULTS BASED ON A PHASE-III TRIAL, European journal of cancer, 33, 1997, pp. 4-4
Authors:
WASSERMAN E
MYARA A
RIOFRIO M
PAUMIER D
HERAIT P
AWAD L
MISSET JL
CVITKOVIC E
Citation: E. Wasserman et al., BILIRUBIN - BASE-LINE VALUE AND TRANSIENT INCREASE OF TOTAL BILIRUBIN(BIL) MAY BE USED AS GOOD PREDICTOR OF CPT-11S TOXICITY, European journal of cancer, 33, 1997, pp. 1110-1110
Authors:
SASTRE J
PAZARES L
DIAZRUBIO E
CORTESFUNES H
CARCAS A
GRUIA G
HERAIT P
FDZCHACON C
MARTIN C
FARR I
Citation: J. Sastre et al., PHASE-I DOSE-FINDING STUDY OF IRINOTECAN (CPT-11) OVER A SHORT IV INFUSION COMBINED WITH A FIXED-DOSE OF 5-FLUOROURACIL (5-FU) PROTRACTED CONTINUOUS IV INFUSION IN PATIENTS WITH ADVANCED SOLID TUMORS, European journal of cancer, 33, 1997, pp. 1141-1141
Authors:
MERROUCHE Y
EXTRA JM
ABIGERGES D
BUGAT R
CATIMEL G
SUC E
MARTY M
HERAIT P
MAHJOUBI M
ARMAND JP
Citation: Y. Merrouche et al., HIGH DOSE-INTENSITY OF IRINOTECAN ADMINISTERED EVERY 3 WEEKS IN ADVANCED CANCER-PATIENTS - A FEASIBILITY STUDY, Journal of clinical oncology, 15(3), 1997, pp. 1080-1086
Authors:
ROUGIER P
BUGAT R
DOUILLARD JY
CULINE S
SUC E
BRUNET P
BECOUARN Y
YCHOU M
MARTY M
EXTRA JM
BONNETERRE J
ADENIS A
SEITZ JF
GANEM G
NAMER M
CONROY T
NEGRIER S
MERROUCHE Y
BURKI F
MOUSSEAU M
HERAIT P
MAHJOUBI M
Citation: P. Rougier et al., PHASE-II STUDY OF IRINOTECAN IN THE TREATMENT OF ADVANCED COLORECTAL-CANCER IN CHEMOTHERAPY-NAIVE PATIENTS AND PATIENTS PRETREATED WITH FLUOROURACIL-BASED CHEMOTHERAPY, Journal of clinical oncology, 15(1), 1997, pp. 251-260
Authors:
CANAL P
GAY C
DEZEUZE A
DOUILLARD JY
BUGAT R
BRUNET R
ADENIS A
HERAIT P
LOKIEC F
MATHIEUBOUE A
Citation: P. Canal et al., PHARMACOKINETICS AND PHARMACODYNAMICS OF IRINOTECAN DURING A PHASE-IICLINICAL-TRIAL IN COLORECTAL-CANCER, Journal of clinical oncology, 14(10), 1996, pp. 2688-2695
Authors:
ARMAND JP
DUCREUX M
MAHJOUBI M
ABIGERGES D
BUGAT R
CHABOT G
HERAIT P
DEFORNI M
ROUGIER P
Citation: Jp. Armand et al., CPT-II (IRINOTECAN) IN THE TREATMENT OF COLORECTAL-CANCER, European journal of cancer, 31A(7-8), 1995, pp. 1283-1287
Authors:
MISSET JL
SALIBA F
GIACCHETTI S
BRAIN E
VASSAL G
BONNAY M
BASTIAN G
COTE C
MAHJOUBI M
HERAIT P
HAGIPANTELLI R
CVITKOVIC E
Citation: Jl. Misset et al., PATHOPHYSIOLOGY AND THERAPY OF IRINOTECAN (CPT-11) INDUCED DELAYED-ONSET DIARRHEA (DD) - A PROSPECTIVE ASSESSMENT, European journal of cancer, 31A, 1995, pp. 742-742
Authors:
CHABOT GG
ABIGERGES D
CATIMEL G
CULINE S
DEFORNI R
EXTRA JM
MAHJOUBI H
HERAIT P
ARMAND JP
BUGAT R
CLAVEL M
MARTY ME
Citation: Gg. Chabot et al., POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF IRINOTECAN (CPT-11) AND ACTIVE METABOLITE SN-38 DURING PHASE-I TRIALS, Annals of oncology, 6(2), 1995, pp. 141-151
Authors:
ABIGERGES D
CHABOT GG
ARMAND JP
HERAIT P
GOUYETTE A
GANDIA D
Citation: D. Abigerges et al., PHASE-I AND PHARMACOLOGICAL STUDIES OF THE CAMPTOTHECIN ANALOG IRINOTECAN ADMINISTERED EVERY 3 WEEKS IN CANCER-PATIENTS, Journal of clinical oncology, 13(1), 1995, pp. 210-221
Authors:
ABIGERGES D
ARMAND JP
CHABOT GG
DACOSTA L
FADEL E
COTE C
HERAIT P
GANDIA D
Citation: D. Abigerges et al., IRINOTECAN (CPT-11) HIGH-DOSE ESCALATION USING INTENSIVE HIGH-DOSE LOPERAMIDE TO CONTROL DIARRHEA, Journal of the National Cancer Institute, 86(6), 1994, pp. 446-449
Authors:
MUNCK JN
ROUGIER P
CHABOT GG
RAMIREZ LH
BOGNEL C
LUMBROSO J
HERAIT P
ELIAS D
LASSER P
GOUYETTE A
Citation: Jn. Munck et al., PHASE-I AND PHARMACOLOGICAL STUDY OF INTRAARTERIAL HEPATIC ADMINISTRATION OF PIRARUBICIN IN PATIENTS WITH ADVANCED HEPATIC METASTASES, European journal of cancer, 30A(3), 1994, pp. 289-294
Authors:
MAHJOUBI M
ROUGIER P
OLIVIERA J
HERAIT P
TIGAUD JM
DROZ JP
Citation: M. Mahjoubi et al., PHASE-II TRIAL OF PIRARUBICIN IN THE TREATMENT OF ADVANCED PANCREATIC-CANCER, Cancer investigation, 12(4), 1994, pp. 403-405
Risultati:
1-17
|